Genentech, Inc.

Walter and Eliza Hall Institute of Medical Research

Abbott Laboratories Corporation

Abbvie Inc.

George Nikolakopoulos

Andrew J Souers

Keith G Watson

John A Flygare

Steven Elmore

Chudi Obioma Ndubaku

Jonathan Bayldon Baell

Wayne J Fairbrother

Andrew M Petros

Danette Dudley

Brad E Sleebs

Chinh Thien Bui

Guillaume Laurent Lessene

Brian John Smith

Peter Colman

Peter Edward Czabotar

Carl Steven Rye

Steven W Elmore

Brad Edmund Sleebs

Danette A Dudley

Xilu Wang

Le Wang

Zhi-Fu Tao

Lisa A Hasvold

Kurt Deshayes

In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X, X, X, X, R, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Compounds and methods of use

In one aspect, the present invention provides for a compound of Formula I in which the variable X, X, X, X, Q, A, R, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Heterocyclic compounds and methods of use

Growing community of inventors

Thomastown, Australia

George Nikolakopoulos